Tag Archives: HEA
Asia Plantation Capital Poised to Develop the Agarwood Industry in Malaysia
SINGAPORE, Aug. 30, 2014 /PRNewswire/ — Asia Plantation Capital (a sustainable plantation company) seeks to develop more opportunities for Agarwood as a beneficial crop in Malaysia.
Asia Plantation Capital at Bio Johor 2014
Aquilaria Saplings in Nursery
Speaking at the biotechnology conference ‘Bio Johor 2014’, Dr Panamas Chetpattananondh (an Associate Professor from the Prince Songkla University in Thailand, and Head of the Scientific Advisory Board at Asia Plantation Capital) presented a plenary paper on the potential for Agarwood in Malaysia. Particular significance was given to the possibilities of utilising the advanced technologies developed by Asia Plantation Capital, and the opportunities that could be created in so doing.
With the value of Oud oil (that which comes from the specially treated wood of the tree), being significantly higher than the value of gold (by a factor of 1.5), the sustainable Agarwood industry is well established in Asia, with Asia Plantation Capital leading the way. The sustainable plantation company is now actively looking to bring their advanced plantation systems to Malaysia.
“Gaharu (Agarwood) is not new to the region and we see many opportunities for its growth in Malaysia. As a leading company in plantation management, we ensure that our agarwood is harvested ethically and sustainably,” said Steve Watts – Chief Executive Officer of Asia Plantation Capital Berhad – speaking at the Johor Biotech Conference. “Not only that,” he continued, “but we are one of the very few plantation companies to have our products certified by CITES (the Convention on International Trade in Endangered Species of Wild Fauna and Flora) which permits us to trade legally in Agarwood.”
Asia Plantation Capital is the main sponsor of the Bio Johor 2014 Biotechnology Conference and Exhibition. APC enjoyed the same privilege last year at the first International Scientific Symposium on Agarwood (ISSA) held in Malaysia, which was organised by Universiti Putra Malaysia.
Agarwood (or Gaharu, as it is more commonly known in Malaysia and Indonesia), comes from the Aquilaria tree – a species native to Southeast Asian countries such as Malaysia, Thailand, Cambodia, Vietnam and Indonesia. What makes Agarwood so highly sought after is the rarity of the fragrant resin contained within. It is produced only when the tree is affected by a certain fungus (or, in the case of trees managed by Asia Plantation Capital, when treated in a specific way).
Oud oil and Oud wood chips have been an integral part of Middle Eastern cultures for centuries, where it is not only used in fragrances, but also in the wood chips burned in homes as incense. In China, Agarwood sculptures are common residential artefacts, and wearing bracelets made of Agarwood beads is fast becoming a popular trend, with recent record prices at auction having been achieved in China for Agarwood pieces.
Globally, Oud is now a major ingredient in the perfume and cosmetic industry, and is used by almost all of the world’s leading, luxury fragrance brands. Asia Plantation Capital’s partner company, Fragrance Du Bois, recently had one of its perfumes shortlisted as a top 10 finalist in the Art and Olfaction Awards (the fragrance industry ceremony held in Los Angeles, USA) matching up with and surpassing competitors from around the world.
The health benefits of Agarwood have been well documented, and have been a mainstay of Traditional Chinese Medicine (TCM) for hundreds of years. Agarwood is renowned to be beneficial in the treatment of digestive system disorders, the relief of spasms and pain, as well as tightness in the chest, abdominal pain, vomiting, diarrhoea and asthma.
Recent research has shown that, potentially, Agarwood has even more medicinal benefits, with the oil having been found to have sedative effects, while a component shows promise for use in the development of an anti-cancer drug. Antioxidant properties have also been found in the extract of Agarwood leaves, which may also be used for the treatment of stomach complaints and skin infections.
“I have spent nine years researching and developing the extraction methods of Agarwood oil to produce better quality oil, and it has made me realise that there is always more to be discovered with this amazing tree,” said Dr Chetpattananondh. She continued, “The sustainable plantation of Agarwood trees could be very valuable to the Malaysian agriculture industry. One significant advantage is that Agarwood grows very well when partnered with banana and other interpolated crops and trees.” The Asia Plantation Capital Scientific Advisory Board is now working with academics across Asia to develop and produce pharmaceuticals from Agarwood for wider use in traditional medicine.
All species of the Aquilaria tree are classified under CITES as endangered species – due to extensive and illegal logging and harvesting for Oud oil. Asia Plantation Capital’s Oud oil and woodchip products are all legally certified under the CITES agreement, ensuring that the strictest ethical and legal standards are upheld in the planting, growing and harvesting of Agarwood and Oud oil.
Moving forward, Asia Plantation Capital has plans to explore further opportunities by acquiring plantations (or partnering existing plantation owners) to develop Agarwood in Malaysia. Over the last 10 years, Asia Plantation Capital has developed advanced proprietary inoculation systems that have been implemented in Thailand, Cambodia and India (with proven results) as well as a new, patented system which, over a longer time frame, will stimulate resin production throughout the entire tree.
- More information about Bio Johor 2014
- More information about the International Scientific Symposium on Agarwood
Notes to Editors:
About Asia Plantation Capital
Asia Plantation Capital is an owner and operator of a diverse range of commercial plantation and farming businesses across the Asia-Pacific region, and globally, is part of the Asia Plantation Capital Group of associated companies. Its focus is on multicultural and diverse plantation projects geared to the domestic and commercial demands of the countries in which they operate. Working closely with, and supporting local communities, is an underlying core principle of the APC business, providing social and cultural support, as well as investment, to move these communities away from deforestation and illegal logging activities, previously seen as a main source of income in some regions of Asia. Established officially in 2008 (although operating privately since 2002) the group now has plantation and agricultural projects on four continents with operational projects at various stages in Thailand, Malaysia, China, Laos, India, Cambodia, Sri Lanka, Mozambique, The Gambia, North America and Europe.
Promoting the use of certified wood is the best way of preventing deforestation, thereby protecting biodiversity and combatting poverty in the tropical rainforest regions. For the yachting sector, which strives for excellence and which is already involved in environmental efforts, this is also a way of ensuring that no wood from illegal logging is used.
About Fragrance Du Bois
Fragrance Du Bois is a niche luxury perfume house working closely with sustainable plantations inAsia, bringing exciting new 100% organic Oud oil based fragrances to exclusive markets worldwide. Sustainably sourcing the finest raw materials across the globe, working with French perfumers to create a full range of products, and also providing bespoke fragrance services, Fragrance Du Bois is personal luxury with a conscience. With exclusive fragrance lounges around the world, in Dubai, Hong Kong, Thailand, Malaysia and Singapore, Fragrance Du Bois creates only the finest experience in bespoke perfumery.
Fragrance Du Bois is known as Parfums Du Bois in France and in non-French speaking markets, as Fragrance Du Bois.
Asia Plantation Capital Pte. Ltd. 50 Collyer Quay, #06-05 OUE Bayfront, Singapore 049321
Tel: +65 6222 3386 | Fax: +65 6221 2197 | Email: pr@asiaplantationcapital.com
Shanghai Pharmaceuticals Achieves Double-Digit Growth of Revenue and Profit for 1H2014
HONG KONG, Aug. 30, 2014 /PRNewswire/ — Shanghai Pharmaceuticals Holding Co., Ltd. (“Shanghai Pharmaceuticals” or the “Company” and, together with its subsidiaries, the “Group; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets, today announced its interim results for the first half of 2014. During the Reporting Period, the Company’s operating revenue was RMB44.013 billion, up by 13.68% as compared with the corresponding period of last year. Net profit attributable to the equity holders of the listed Company was RMB1.318 billion, representing an increase of 10.79% as compared with the corresponding period of last year. The operating profit margin after deducting sales and administration expenses was 4.11%, up by 0.08 percentage point from the corresponding period of last year. Basic earnings per share amounted to RMB0.4902, which laid solid foundation to ensure that the objectives for operating budget are achieved throughout the year.
In the first half of 2014, based on the overall arrangements for the new round of the three year development plan for 2013-2015 and the budgetary arrangements made at the beginning of 2014, and guided by the core values which were “innovation, integrity, cooperation, inclusiveness and responsibility”, the Company proactively built a V-shaped collaborative team, started to optimize the marketing and research and development (“R&D”) systems, continued to carry out Lean Six Sigma management projects, comprehensively optimized the organizational structure, deepened the integration of internal resources and proactively promote the external merge and acquisition to effectively control operational risks.
Optimize the R&D system, and enhance the innovation capability
In the first half of 2014, the Company established the science and technology innovation council of the Group to participate in the material decision making process in respect of the R&D, and formulated a program for controlling and assessing the Group’ R&D system with Central Research Institute as the core. In addition to the six branches, the Company set up the No.1 Biochemical Branch under the Central Research Institute, which built a solid foundation for the efficient R&D system. During the Reporting Period, the Company’s R&D expenses amounted to a total of RMB208.9 million , accounting for 3.67% of the Company’s manufacturing sales revenue.
In the first half of 2014, sales revenue from the Company’s new products launched in recent years through R&D amounted to RMB556 million, representing 9.78% of the Company’s manufacturing sales revenue. The proportion of new products has been further increased.
In respect of the R&D of the antibody drugs, the application for pharmaceutical clinical trial on “Recombinant humanized anti-CD20 monoclonal antibody injection” has been accepted by China Food and Drug Administration on May 2014, and passed the registration test and quality standards review by the National Institutes for Food and Drug Control of China. “Recombinant fusion protein of human tumor necrosis factor receptor mutant and Fc fragment injection”, a medicine co-developed with Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., has been granted a pharmaceutical clinical approval on May 2014, to enter the clinical trial stage. In addition, the Company launched the plan for the construction of the Group’s antibody industrialisation base.
In respect of the R&D of Chinese medicine, since its establishment, the Chinese Medicine Research Institute under the Shanghai Pharmaceuticals Central Research Institute has launched the two projects of secondary development for Chinese medicine products, i.e. Babaodan and Wanbi Tablets. The company also cooperated with the Eastern Hepatobiliary Surgery Hospital subordinated to The People’s Liberation Army Second Military Medical University of China (“Second Military Medical University”) and Shanghai Institutes for Biological Sciences under Chinese Academy of Sciences (“CAS”).
In respect of the R&D of bio-chemical drugs, on April 2014, the approvals were granted to the LLTD-8, a new drug under class 1.1, for the extended clinical trial of phase I, and it was permitted to enter into the extended clinical research of phase I. The Company also developed the plan for the construction of the Group’s industrialization base for chemical active pharmaceutical ingredients (API).
Besides, the Company confirmed 13 innovation co-operation projects under the cooperation of “Translational Medicine Alliance” with the Second Military Medical University.
Main business improved steadily
In the first half of 2014, the Company’s sales revenue from the pharmaceutical business was RMB5.687 billion, representing a growth of 3.27% as compared with the corresponding period of last year; its gross profit margin was 47.79%, increased by 0.63 percentage point as compared with the corresponding period of last year. The Company realized sales revenue of RMB3.347 billion from its 64 key products, an increase of 3.92% as compared to the corresponding period of last year and accounting for 58.85% of the revenue from manufacturing sales with an average gross profit margin of 62.82%, and the average growth rate of the top five products with the highest growth rate amounted to 68.08%. In the first half of 2014, 22 products achieved sales revenue of more than RMB50 million, and the sales revenue of these products amounted to RMB2,565 million, accounting for 45.10% of the manufacturing sales.
Shanghai Pharmaceuticals’ marketing centres have set up a work operating mechanism and defined the principle of dividing various marketing departments by products and devised basic workflows since establishment. In the future, marketing centres will continue to increase its capability in making academic promotion by hospital distribution points, conducting depth distribution, and engaging in investment promotion and agency for products, will focus on 64 key products, and to formulate and define marketing target and strategy of key products and to track its implementation, in order to meet progress target.
Recently, 300 products of the Company were listed on List of Low-price Drugs Among the Pricing Range Set by the National Development and Reform Commission. 10 exclusive products or exclusive dosage forms of the Company, including Weifuchun tablets were on the list, which is expected to have positive impact on the operation results of the Company.
In the pharmaceutical distribution business, Shanghai Pharmaceutical achieved sales revenue of RMB38.51 billion in the first half of this year, an increase of 15.17% year on year; gross profit margin 6.02%, dropped 0.09 percentage points compared with the same period last year. In response to the pressure on gross margin of distribution industry, the Company continued to optimize its product structure to maintain a reasonable proportion of direct sales and promote Lean Six Sigma projects to strengthen cost control. After deducting the SG&A expenses, operating margin rose 0.25 percentage points over the same period last year to 2.78 %, operational efficiency has gradually been improved by expanding the distribution scale.
Through mergers and acquisitions, the Company has begun a nationwide distribution network, focusing on covering the east, north and south of the three key regions with strong competitiveness. The sales in East China regional accounted for 66.81%, North China regional sales accounted for 24.32%, South China regional sales accounted for 6.11%. Meanwhile, Shanghai Pharmaceutical’s active and innovative business models committed to providing customers with quality terminal network and value-added services. The Company service of innovative supply chain and high-end direct-to-patients (DTP) was currently used by a total number of 60 hospital pharmacies. Besides, it continued to maintain rapid growth in vaccines and other high-value consumables business and thus achieved sales of RMB2.77 billion in the first half of year, an increase of 41.46%.
Deepened internal integration, promoted external acquisitions
In the first half of this year, Shanghai Pharmaceutical continued to strengthen internal integration and sharing of resources, improve capital efficiency and reduce financial costs, promote internal manufacturing and distribution synergies, establish market access platform, unify and coordinate throughout tendering and resource allocation. In addition, the Company continued to promote centralized procurement of bulk herbs, packing materials and stationary, and develop Lean Six Sigma management actively so that cost efficiency and profitability are improved.
To further expand the pharmaceutical distribution network, the Company acquired 50% equity interest in Beijing Xin Hai Feng Yuan Biopharma Technology Development Co., Ltd., 85% equity interest in Shaanxi Huaxin Pharmaceutical Co., Ltd. and a 100% equity interest in Ordos Yili Pharmaceutical Co., Ltd. To further expand the pharmaceutical distribution network in Shandong, it acquired 75% equity interest in Shandong SPH Pharmaceutical Co., Ltd., and increased its holding in Shandong SPH Shanglian Pharmaceutical Co., Ltd. to 35% equity interest. To strengthen international cooperation in research and development of innovative drugs, enhance the quality of pharmacodynamics studies on new drugs, the Company made an equity investment by establishing Sichuan Green Tech Biotechnology Co., Ltd. In order to focus on its principle business, Shanghai Medical Devices Co., Ltd. under the Company transferred its 75% stake of Shanghai Shengli Medical Instruments Co., Ltd.
Subsequent progress of Babaodan
During the Reporting Period, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (hereinafter referred as “Pientzehuang”) filed to the Intermediate People’s Court of Zhangzhou City a lawsuit (hereinafter referred as the “lawsuit”), in relation to an unfair competition dispute, against Xiamen Traditional Chinese Medicine Co., Ltd. (hereinafter referred as “Xiamen Traditional Chinese Medicine”), Xiamen Evening News Media Development Co., Ltd. and Xiamen Daily Press. On 13 March 2014, Xiamen Traditional Chinese Medicine submitted its objection to the jurisdiction to the Intermediate People’s Court of Zhangzhou City. On 18 June, Xiamen Traditional Chinese Medicine Co., Ltd. submitted its objection to the Trademark Office of The State Administration For Industry & Commerce of the People’s Republic of China (hereinafter referred as “Trademark Office of The State Administration For Industry & Commerce”) with respect to the trademarks of “Babaodan Pien Tze Huang” (application number: 11683990) and “Pien Tze Huang Babaodan” (application number: 11683929), registered by Zhangzhou Pientzehuang
Pharmaceutical Co., Ltd on 1 Nov 2012 under the Class 5 of “Chinese Medicine”, requiring the Trademark Office of The State Administration For Industry & Commerce to revoke the registration of the two aforesaid trademarks. Until now, the case is still under investigation procedure. On 23 June 2014, Xiamen Traditional Chinese Medicine received the civil judgment ((2014) Min Min Zhong Zi No. 660), and the Higher People’s Court of Fujian Province finally judged that the lawsuit shall be transferred to the jurisdiction of Xiamen Intermediate People’s Court. On 18 August 2014, the Xiamen Traditional Chinese Medicine received the Notice (2014) Xia Min Zi Di No. 937 issued by the Intermediate Court of Xiamen City, Fujian Province, pursuant to which the case in question was designated by the Higher People’s Court of Fujian Province to be in the jurisdiction of the Intermediate Court of Fuzhou City.
About Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharmaceuticals is the only integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets with top-three scale in China, providing solutions in pharmaceutical manufacturing, distribution, logistics storage and retail. The Group currently offers more than 800 pharmaceutical products to more than 11,000 hospitals and medical institutions in China. The Group also operates approximately more than 1,700 self-operated and franchise stores nationwide.
For further information, please contact:
|
Porda Havas International Finance Communications Group |
||
|
Kelly Fung |
+852 3150 6763 |
|
|
Angie An |
+852 3150 6736 |
|
|
Kit Ng |
+852 3150 6705 |
|
|
Victoria Huang |
+852 3150 6731 |
|
|
Fax: +852 3150 6728 |
||
Valurise Health Solutions was Awarded the 2014 Red Herring Top 100 Asia, being the Only Healthcare Service Enterprise in Asia Receiving the Very Award
HONG KONG, August 29, 2014 /PRNewswire/ — Valurise Health Solutions (“VHS”) was awarded as the 2014 Red Herring Top 100 Asia Winner, being the only award-winning healthcare service company, standing out from creative leading companies in As…
New Opportunities for Operators in the Blended Reality Era
– Ensuring Relevance in a Mobile, Quantified, and Augmented World
LONDON, Aug. 29, 2014 /PRNewswire/ — Frost & Sullivan will share insights on the most important trends in the European mobile industry and how they will affect existing value chains and business models. We highlight important developments and what they mean for your business.
The conference will be followed by a live question-and-answer session that will take place on Tuesday, 9 September 2014 at 3 p.m. BST.
Frost & Sullivan’s Information and Communication Technologies experts Senior Analyst Sheridan Nye and Consultant Lawrence Lundy will highlight the critical developments, the changing value, and growth in the Europe’s mobile industry. This online conference will:
- Explore advancements in mobile devices, including health monitoring and wireless transactions
- Identify the disruptive threats and opportunities
- Recommend strategies on how operators can adapt and remain relevant
“Mobile operators face multiple challenges in an intensely competitive environment where once-reliable sources of profit are fast evaporating. One way to fend off the threats is to emulate their fiercest competitors. This means looking ‘inside-out’ to become more agile digital businesses,” explains Sheridan Nye.
Mobile ecosystem participants need to prepare for the quantified and automated world. “When data is the currency of the future, the only sustainable competitive advantage is trust,” emphasizes Lawrence Lundy.
To participate in this complimentary web conference, please email Edyta Grabowska Corporate Communications, at edyta.grabowska@frost.com with your full contact details. Upon receipt of the above information, a registration link will be e-mailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation
Contact:
Edyta Grabowska
Corporate Communications – Europe
P: +48 22 481 62 03
E: edyta.grabowska@frost.com
Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014
— Innovative cardiology solutions help deliver better care for more patients, respond to biggest challenges facing cardiologists
ANDOVER, Mass., Aug. 29, 2014 /PRNewswire/ – Royal Philips (NYSE: PHG AEX: PHIA) today announced its presence at the European Society of Cardiology (ESC) Congress 2014, where the company is highlighting the full range of its cardiology solutions serving clinicians and patients across the care continuum from prevention and diagnosis, to treatment, recovery and wellness. Visitors to the Philips booth (#F500) will experience Philips’ new Cardiology Solutions approach, enabling clinicians and health systems to deliver better cardiovascular care for more patients, at lower a cost, in the treatment of coronary artery disease, structural heart disease, and heart failure.
Photo – http://photos.prnewswire.com/prnh/20140828/141270
Photo – http://photos.prnewswire.com/prnh/20140828/141271
Photo – http://photos.prnewswire.com/prnh/20140828/141269
Photo – http://photos.prnewswire.com/prnh/20140828/141268
Photo – http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
Philips Cardiology Solutions meet the needs of clinicians who are at the center of the cardiovascular care. Philips’ breadth of diagnostic and treatment solutions offer real-time tools to connect patient information with clinician knowledge, resulting in more personalized care, while innovations for recovery and wellness provide a safer transition from hospital to home.
“Interventional cardiology is continuously innovating new procedures to improve the lives of patients around the world,” said Gene Saragnese, CEO of Imaging Systems for Philips Healthcare. “Our cardiology solutions approach unlocks the data and insights necessary to improve efficiency in interventional cardiology, and together with our global customers and partners, we’re creating care delivery to optimally support clinicians and patients.”
One of the leading global conferences on cardiovascular care, the ESC Congress 2014 will showcase the industry’s most promising research and leading innovations. Throughout the event, Philips and physician partners will be participating in several symposia and presentations on topics including big data in cardiology and anatomical intelligence.
On Saturday, August 30th, Philips’ newest ultrasound system will make its worldwide debut, with an unveiling at the Philips Booth (#F500) at 4 p.m. CET. Beginning August 30th and running through September 3rd at the ESC Congress 2014, Philips will also offer demonstrations of its advanced imaging and ultrasound solutions designed for every step of the patient journey, including:
Screening and Diagnosis
- ST80i ECG Stress Testing System – Manages patient information from start to finish through bi-directional network connectivity and turns stress ECG data into actionable insights.
- Philips IntelliSpace ECG – A multi-modality, multi-vendor, scalable ECG management system, providing access to patient data for review of time-sensitive ECGs on a smartphone, to help improve patient care through comprehensive and flexible workflow management.
- Xcelera Image Management System – Integrated, multi-modality image management system for cardiovascular information offering access to multiple applications within a single flexible workspace for use in multiple locations and across multi-sites.
- IntelliSpace Portal with TAVI package – Quickly assesses the aortic root anatomy for pre-TAVI planning and obtains crucial information about eligibility, proper device size, and a recommendation for C-arm angle for device deployment.
- EPIQ Ultrasound – Philips’ most powerful architecture ever applied to ultrasound imaging.
Treatment
- Allura Clarity with ClarityIQ – Industry-leading interventional X-ray system offering high image quality at a low [X-ray] dose.
- EchoNavigator R2 with Image Fusion – Fuses live X-ray and live echo for intuitive, live image guidance during structural heart disease procedures.
- Hybrid OR – Provides the ability to seamlessly perform a wide range of open and minimally invasive procedures in a single room.
- Heart Navigator – Supports structural heart disease procedures by simplifying planning, device and projection angle selection and providing live image guidance to support device positioning.
Recovery and Care Management
- Q-Station, with anatomical intelligence tools – Streamlines ultrasound data management and performs advanced visualization, analysis and quantification of Philips echo data.
- Motiva mobile – A content rich and interactive telehealth platform that is part of the Chronic Ambulatory Care program (eCAC), specifically designed to help empower chronically ill patients to effectively manage their disease state.
For more information on Philips presence at the ESC Congress 2014, please visit http://www.philips.com/esc, follow the #ESCcongress conversation @PhilipsHealth and continue the conversation via the Philips LinkedIn Innovations in Cardiology Group.
For more information, please contact:
Kathy O’Reilly
Philips Healthcare
Tel: +1 978-659-2638
Mobile: +1 978-221-8919
Email: kathy.oreilly@philips.com
Twitter: @kathyoreilly
About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 113,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.
